Reports
Sale
Australia and New Zealand PCR Systems Market Size, Share: By Product: Reagents and Consumables, Instruments, Software and Services; By Technique: Conventional PCR, Real-time PCR, Digital PCR, Reverse Transcription PCR, Hot-start PCR, Multiplex PCR, Other PCR Techniques; By Application; Regional Analysis; Supplier Landscape; 2024-2032
Australia and New Zealand PCR Systems Market Outlook
The Australia and New Zealand PCR systems market size is expected to be driven by the rising demand from Asia Pacific PCR systems market, which is likely to grow at a CAGR of 8.4% during the forecast period of 2024-2032. The market growth is likely to be driven by increasing emphasis on preventing pathogen associated infections and technical advancements in the medical research domain.
Australia and New Zealand PCR Systems Market Overview
PCR systems play a critical role in diagnostics and are employed in various applications. It is a fundamental tool in molecular biology, clinical diagnostics, forensic analysis as well as genetic engineering. The PCR systems are witnessing an overall growth in the Asia Pacific region, especially post the COVID-19 pandemic. However, developed nations such as Australia and New Zealand are experiencing key developments, in terms of infrastructure development, rising approvals from regulatory bodies, and new product launches. Such factors are likely to fuel the Australia and New Zealand PCR systems market share in the forecast period.
New Product Launches in the Market
In November 2023, Roche , launched LightCycler® PRO System, a next generation qPCR based on gold standard technology of the LightCycler® Systems. Acting as a bridging gap between translational research and in vitro diagnostics, the new system improves the quality and usability by multiple folds. It is developed to facilitate both research as well as IVD workflows, allowing labs to operate between discovery as well as evaluating the clinical samples of patients. With an aging population on the rise, the introduction of technologies that can be used in multiple application areas, which is expected to drive the Australia and New Zealand PCR systems market growth.
Increased Application Across Various Medical Domains
PCR systems are employed across various medical domains to offer advanced and precise testing, multiple companies are collaborating to bring new products in the market. In March 2023, Stilla Technologies and Atila BioSystems announced their partnership to co-develop digital PCR kits and assays that can be used in oncology diagnostics. In Australia, the cancer cases are expected to increase, with a significant rise in the population. In 2023, around 165,000 cancer cases were diagnosed in the region. Early detection of cancer can help in better treatment and help in decreasing the mortality rate significantly. As a result, the new digital PCR system can be used to detect the presence of circulating tumor DNA (ctDNA) from liquid biopsy samples taken from patients affected from commonly occurring cancers such as breast, lung, melanoma, prostate, and colorectal cancers.
Surge in Approvals from Regulatory Authorities
The Australia and New Zealand PCR systems market demand is likely to witness significant growth owing to the rise in approvals.In March 2023, BGI Genomics Multiplex Real-time Fluorescent RT-PCR Kit received the market access qualification to enter the Australian Register of Therapeutic Goods. Used for detecting SARS-CoV-2, Influenza A Virus and Influenza B Virus, the kit can be used to detect all three viruses simultaneously. The approval is major indicator of the ongoing market trend, wherein the regulatory authorities are allowing new testing kits to prevent infections, particularly during the flu season. It also improves the testing efficiency and helps clinicians in modifying their therapeutic regimen based on the patient’s condition.
Australia and New Zealand PCR Systems Market Segmentation
Market Breakup by Product
- Reagents and Consumables
- Instruments
- Software and Services
Market Breakup by Technique
- Conventional PCR
- Real-time PCR
- Digital PCR
- Reverse Transcription PCR
- Hot-start PCR
- Multiplex PCR
- Other PCR Techniques
Market Breakup by Application
- Gene Expression Analysis
- Genetic Sequencing
- Genotyping
- Nucleic Acid Detection
- Nucleic Acid Synthesis
- Standard Validation/Verification
- Diagnostic Applications
- Environmental Applications
- Others
Market Breakup by End User
- Hospitals and Diagnostic Centres
- Healthcare Industries
- Academia and Government Organisations
- Pharma-biotech Companies
- Applied Industries
- Other End Users
Market Breakup by Country
- Australia
- New Zealand
Australia and New Zealand PCR Systems Market Regional Analysis
Australia is likely to lead the PCR systems market share in the coming years owing to the rising investments by government to improve the healthcare and research infrastructure. In addition, the presence of a stringent regulatory framework also fuels the market size.
New Zealand is also experiencing significant PCR systems market growth with a surge in partnerships between prominent companies and emerging start-ups to develop effective solutions for the patients. The healthcare and pharmaceutical sector is witnessing significant expansion in the region, owing to an increase in the aging population and rising investments to prevent infections, mitigate the mortalities associated with chronic diseases and ensuring patient safety.
Australia and New Zealand PCR Systems Market: Competitor Landscape
In April 2023, Thermo Fisher Scientific Inc., partnered with ALPCO-GeneProof to bring the TaqPath Menu | GeneProof PCR kits to market. Based on ALPCO GeneProof’s ‘one workflow’ technology, the new product line adds to Thermo Fisher’s exhaustive list of molecular diagnostic assays, and it helps in detecting bloodborne and sexually transmitted infections (STIs). Additional panels for common infections such as transplant and immunocompromised, vector-borne diseases are expected to follow in coming years. The expansion of services with the incorporation of new products is a major market trend that is being adopted by several prominent healthcare companies.
The key features of the Australia and New Zealand PCR systems market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific Inc.
- Roche Diagnostics (a division of F. Hoffmann-La Roche Ltd)
- Bio-Rad Laboratories, Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- Abbott Laboratories
- Danaher Corporation
- bioMérieux SA
- PerkinElmer, Inc.
- Fluidigm Corporation
- Eppendorf AG
- Promega Corporation
- Analytik Jena AG (Endress+Hauser Group)
- Illumina, Inc.
- Becton, Dickinson, and Company (BD)
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Technique |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand PCR Systems Market Overview
3.1 Australia and New Zealand PCR Systems Market Historical Value (2017-2023)
3.2 Australia and New Zealand PCR Systems Market Forecast Value (2024-2032)
4 Australia and New Zealand PCR Systems Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Australia and New Zealand PCR Systems Market Segmentation
5.1 Australia and New Zealand PCR Systems Market by Product
5.1.1 Market Overview
5.1.2 Reagents and Consumables
5.1.3 Instruments
5.1.4 Software and Services
5.2 Australia and New Zealand PCR Systems Market by Technique
5.2.1 Market Overview
5.2.2 Conventional PCR
5.2.3 Real-time PCR
5.2.4 Digital PCR
5.2.5 Reverse Transcription PCR
5.2.6 Hot-start PCR
5.2.7 Multiplex PCR
5.2.8 Other PCR Techniques
5.3 Australia and New Zealand PCR Systems Market by Application
5.3.1 Market Overview
5.3.2 Gene Expression Analysis
5.3.3 Genetic Sequencing
5.3.4 Genotyping
5.3.5 Nucleic Acid Detection
5.3.6 Nucleic Acid Synthesis
5.3.7 Standard Validation/Verification
5.3.8 Diagnostic Applications
5.3.9 Environmental Applications
5.3.10 Others
5.4 Australia and New Zealand PCR Systems Market by End User
5.4.1 Market Overview
5.4.2 Hospitals and Diagnostic Centres
5.4.3 Healthcare Industries
5.4.4 Academia and Government Organisations
5.4.5 Pharma-biotech Companies
5.4.6 Applied Industries
5.4.7 Other End Users
5.5 Australia and New Zealand PCR Systems Market by Country
5.5.1 Market Overview
5.5.2 Australia
5.5.3 New Zealand
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication Year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by Year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 Thermo Fisher Scientific Inc.
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 Roche Diagnostics (a division of F. Hoffmann-La Roche Ltd)
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 Bio-Rad Laboratories, Inc.
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 QIAGEN N.V.
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Agilent Technologies, Inc.
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 Abbott Laboratories
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 Danaher Corporation
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 bioMérieux SA
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 PerkinElmer, Inc.
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Fluidigm Corporation
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 Eppendorf AG
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 Promega Corporation
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
11.13 Analytik Jena AG (Endress+Hauser Group)
11.13.1 Financial Analysis
11.13.2 Product Portfolio
11.13.3 Demographic Reach and Achievements
11.13.4 Mergers and Acquisitions
11.13.5 Certifications
11.14 Illumina, Inc.
11.14.1 Financial Analysis
11.14.2 Product Portfolio
11.14.3 Demographic Reach and Achievements
11.14.4 Mergers and Acquisitions
11.14.5 Certifications
11.15 Becton, Dickinson and Company (BD)
11.15.1 Financial Analysis
11.15.2 Product Portfolio
11.15.3 Demographic Reach and Achievements
11.15.4 Mergers and Acquisitions
11.15.5 Certifications
12 Australia and New Zealand PCR Systems Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
15.1 Government Funded
15.2 Private Insurance
15.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The Australia and New Zealand PCR systems market size is expected to be driven by the rising demand from Asia Pacific PCR systems market, which is likely to grow at a CAGR of 8.4% during the forecast period of 2024-2032.
The increasing incidence of product launches, equipped with latest technologies along with the growing geriatric population and prevalence of chronic illnesses, is fuelling market demand in the region.
Surge in product approvals from the regulatory authorities is a major market trend. In March 2023, BGI Genomics Multiplex Real-time Fluorescent RT-PCR Kit received the market access qualification to enter the Australian Register of Therapeutic Goods to detect SARS-CoV-2, Influenza A Virus, and Influenza B Virus.
Based on product types, the market is divided into reagents and consumables, instruments, software, and services.
Major end users include hospitals and diagnostic centres, healthcare industries, academia and government organisations, pharma-biotech companies, and applied industries, among others.
Conventional PCR, real-time PCR, digital PCR, reverse transcription PCR, hot-start PCR, and multiplex PCR, among others are common techniques available in the market.
Common application areas include gene expression analysis, genetic sequencing, genotyping, nucleic acid detection, nucleic acid synthesis, standard validation/verification, diagnostic applications, and environmental applications, among others.
Based on country, the market can be divided into Australia and New Zealand.
Key players involved in the market are Thermo Fisher Scientific Inc., Roche Diagnostics (a division of F. Hoffmann-La Roche Ltd), Bio-Rad Laboratories, Inc., QIAGEN N.V., Agilent Technologies, Inc., Abbott Laboratories, Danaher Corporation, bioMérieux SA, PerkinElmer, Inc., Fluidigm Corporation, Eppendorf AG, Promega Corporation, Analytik Jena AG (Endress+Hauser Group), Illumina, Inc. and Becton, Dickinson and Company (BD).
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2199
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3299
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4399
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5499
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER